Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

PloS one - 30 Sept 2009

Dubreuil Patrice, Letard Sébastien, Ciufolini Marco, Gros Laurent, Humbert Martine, Castéran Nathalie, Borge Laurence, Hajem Bérengère, Lermet Anne, Sippl Wolfgang, Voisset Edwige, Arock Michel, Auclair Christian, Leventhal Phillip S, Mansfield Colin D, Moussy Alain, Hermine Olivier

Abstract excerpt

BACKGROUND: The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT. METHODOLOGY...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Bone Marrow Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Inhibitory Concentration 50

Share to Piperidines

Share to Proto-Oncogene Proteins c-kit

Share to Pyridines

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 19789626
DOI: 10.1371/journal.pone.0007258
PMCID: PMC2746281

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19789626-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.PMID 19789626Read ↗

Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disordersSemantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.Semantic proximity Read ↗

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.Semantic proximity Read ↗

Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.Semantic proximity Read ↗

C-KIT signaling in cancer treatment.Semantic proximity Read ↗

The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR).Semantic proximity Read ↗

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.Semantic proximity Read ↗

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.Semantic proximity Read ↗

Targeting c-Kit mutations: basic science to novel therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.